Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Carcinoma, Renal Cell 27Neoplasms 14Neoplasm Metastasis 14Glioblastoma 14Prostatic Neoplasms 13Lymphoma, Mantle-Cell 11Breast Neoplasms 11Brain Neoplasms 11Sarcoma 10Lymphoma, Non-Hodgkin 10Kidney Neoplasms 10Endometrial Neoplasms 10Melanoma 9Gliosarcoma 8Multiple Myeloma 7Glioma 7Ovarian Neoplasms 6Carcinoma, Hepatocellular 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Oligodendroglioma 5Lymphoma, Follicular 5Lymphoma 5Hodgkin Disease 5Central Nervous System Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Astrocytoma 5Waldenstrom Macroglobulinemia 4Uterine Cervical Neoplasms 4Unspecified Adult Solid Tumor, Protocol Specific 4Rhabdomyosarcoma 4

Interventions

Imatinib Mesylate 142nilotinib 94Cyclophosphamide 91fludarabine phosphate 75fludarabine 67Dasatinib 63Mycophenolic Acid 60Whole-Body Irradiation 59Tacrolimus 47Busulfan 45Cyclosporine 36Peripheral Blood Stem Cell Transplantation 35Cytarabine 35Melphalan 30bosutinib 27ponatinib 26Granulocyte Colony-Stimulating Factor 26thymoglobulin 25Thiotepa 25Methotrexate 25Filgrastim 25asciminib 24Antilymphocyte Serum 24Stem Cell Transplantation 22Sirolimus 17Interferon-alpha 16sargramostim 15Cord Blood Stem Cell Transplantation 14Clofarabine 13Bone Marrow Transplantation 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myelogenous, Chronic, BCR-ABL Positive × temsirolimus × Clear all
NCT00101088 2013-01-14

Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

National Cancer Institute (NCI)

Phase 1 Terminated
21 enrolled
MyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡